Skip to main content
VRDN
NASDAQ Life Sciences

Lumvoa's First Launch Quarter Brings $24.7M, Beating Management's Own Expectations

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$27.09
Mkt Cap
$2.849B
52W Low
$13.18
52W High
$34.29
52W Position info
106% above low
Off High info
21% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

VRDN has more than doubled off its 52-week low of $13.18 on elevated volume (2.2× avg).

Summary

Viridian's first commercial quarter for Lumvoa in thyroid eye disease generated $25.8 million in net product revenue, with more than 100 patients on therapy as of September 30. Management said the launch has exceeded expectations, and CMS granted a permanent J-code effective January 1, 2027, which should smooth reimbursement. The company ended the quarter with $955.2 million in cash and says that plus future Lumvoa and elegrobart revenue funds the business through profitability, though the Q3 net loss widened to $101.2 million from $34.6 million a year ago on commercial build-out, a loss of 81 cents a share. Next up: elegrobart BLA submission targeted for Q1 2027, VRDN-292 phase 1 initiation in Q4 2026, and VRDN-008 phase 1 data plus FcRn portfolio plans in Q4 2026. The 8:00 a.m. ET call today will carry the launch trajectory detail.

At the time of this announcement, VRDN was trading at $27.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

VRDN - Latest Insights

VRDN
Nov 09, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $30.00
Real-time Price: $30.91 info
Change: +$0.910 (+3%) info
Market Cap: $3.503B info
VRDN
Nov 04, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.75
Real-time Price: $30.91 info
Change: +$3.16 (+11%) info
Market Cap: $3.503B info
VRDN
Aug 06, 2026, 7:31 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.87
Real-time Price: $30.91 info
Change: +$10.04 (+48%) info
Market Cap: $3.503B info
VRDN
Aug 06, 2026, 7:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.50
Real-time Price: $30.91 info
Change: +$9.41 (+44%) info
Market Cap: $3.503B info
VRDN
Aug 06, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.81
Real-time Price: $30.91 info
Change: +$10.10 (+49%) info
Market Cap: $3.503B info